SG&A Efficiency Analysis: Comparing Viatris Inc. and Travere Therapeutics, Inc.

SG&A Efficiency: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding operational efficiency is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Travere Therapeutics, Inc. over the past decade.

Viatris Inc.: A Giant in the Field

Viatris Inc., a major player, has consistently demonstrated high SG&A expenses, peaking at approximately $4.65 billion in 2023. This represents a staggering 210% increase from 2014, reflecting its expansive operations and market reach.

Travere Therapeutics, Inc.: A Rising Star

Conversely, Travere Therapeutics, Inc. has shown a more modest growth in SG&A expenses, rising from $59.6 million in 2014 to $265.5 million in 2023. This 345% increase highlights its strategic investments in growth and innovation.

Conclusion

While Viatris Inc. showcases the scale of a pharmaceutical giant, Travere Therapeutics, Inc. exemplifies the agility of a growing company. Both paths offer unique insights into the industry's dynamics.